<DOC>
	<DOC>NCT00651105</DOC>
	<brief_summary>The purpose of this study is to assess the GLP-1 and non-GLP-1 effects of LAF237 on glucagon secretion, using treatment observations of the overall glycemic response.</brief_summary>
	<brief_title>Effect of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<criteria>Inclusion criteria Type2 Diabetes Patients Male or female patients aged 30 to 75 years with Type2 Diabetes Mellitus (T2DM) and who are in otherwise good health Must have been diagnosed with T2DM at least 6 months prior to screening, and whose diabetes is controlled by diet and exercise alone or by stable dosage ( &gt; 3 months) of metformin HbA1c in the range of 6.5% to 9% at screening Inclusion Criteria Healthy Volunteers Male or female subjects aged 30 to 75 years, determined to be in good health Normal oral glucose tolerance test (OGTT) at screening Age, gender and weight matched to subjects with T2DM Exclusion criteria Type2 Diabetes Patients A history of: Type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes, e.g., Cushing's syndrome and acromegaly Acute metabolic diabetic complications (such as ketoacidosis or hyperosmolar state (coma)) within the past 6 months Torsades de Pointes, ventricular tachycardia or ventricular fibrillation Any severe hypoglycemic episode within 3 months of screening Use of any of the following medications: Antihypertensive or lipidlowering agents unless on a stable dose for at least 3 months prior to screening Chronic insulin treatment (&gt; 4 weeks of treatment in the absence of an intercurrent illness) within the past 6 months Chronic oral/intramuscular/intravenous corticosteroid treatment ( &gt; 7 consecutive days of treatment) within 8 weeks prior to screening Exclusion Criteria Healthy Volunteers First degree relative of an individual with T2DM History of gestational diabetes Use of any prescription medication within 1 month prior to dosing. Use of overthecounter medications or vitamins within 14 days prior to dosing. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Hyperglycemia</keyword>
	<keyword>Healthy</keyword>
	<keyword>Vildagliptin</keyword>
	<keyword>Adults</keyword>
</DOC>